Slide Session 5: Antiretroviral Chemotherapy I

11   DPC 681 and DPC 684: Resistance and Cross- Resistance Profiles of Second Generation HIV Protease Inhibitors.

12   A Femtomolar HIV-1 Protease Inhibitor with Subnanomolar Activity against Multidrug Resistant HIV-1 Strains.

13   TMC120, a New Non- Nucleoside Reverse Transcriptase Inhibitor, Is a Potent Antiretroviral in Treatment Naive, HIV-1 Infected Subjects.

14   A 14-Day Assessment of the Safety, Pharmacokinetics, and Antiviral Activity of T-1249, a Peptide Inhibitor of Membrane Fusion.

15   AI424-007: 48-Week Safety and Efficacy Results from a Phase II Study of a Once-Daily HIV-1 Protease Inhibitor (PI), BMS-232632.

16   Antiretroviral Therapy (ART) Plus Cyclophosphamide (CTX) To Diminish HIV DNA in Lymphoid Tissue.

17   Prospective, Randomized, Controlled Phase II Study of Highly Active Antiretroviral Therapy (HAART) with Continuous IV (CIV) or Subcutaneous (SC) Interleukin-2 (IL-2) in HIV-Infected Patients with CD4+ Counts of 50—350 cells/mm³: ACTG 328-Final Results at 84 Weeks.

18   Two Randomized, Controlled, Equivalence Trials of Emtricitibine (FTC) to Lamivudine (3TC).

19   Severe Liver Toxicity in Patients Receiving Two Nucleoside Analogues and a Non-Nucleoside Reverse Treanscriptase Inhibitor.

20   Successful Substitution of Protease Inhibitors with Efavirenz (EFV) in Patients with Undetectable Viral Loads - A Prospective, Randomized, Multicenter, Open-Label Study (DMP 049).